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autoimmune or autoaggressive disease.
The new climax of research on Perforin,
as reported here, may soon be followed
by the development of novel therapeutics
targeted to enhance or diminish Perforin
cytotoxicity, to enhance our fitness and
survival.
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Milky spots are located in the omentum of the peritoneal cavity and their classification as lymphoid organs
has been debated. In this issue of Immunity, Rangel-Moreno et al. (2009) provide compelling data to consider
them as unique secondary lymphoid organs.The omentum is formed by a double layer
of mesothelial cells that connects the
stomach,pancreas, spleen,andcolon (Wil-
liams and White, 1986). Embedded within
the omentumare opaquestructures,which
are clusters of leukocytes, called milky
spots. Milky spots are mainly composed
of macrophages and B1 cells, resembling
thecellular composition found in theperito-
nealcavity.B1cells formauniquesubsetof
B cells that can be distinguished from
conventional B (B2) cells by expression of
distinct cell-surface markers and antigen
receptors that can bind common bacterial
epitopes, as well as by their recognized
potential to produce natural antibodies
that provide a first protection to bacterial
infections. B1 cells are localized in distinct
anatomical locations, such as the perito-
neal and pleural cavities, but are also
present in the spleen. For their localization
to these body cavities, but not the spleen,
the chemokine CXCL13 is of great impor-
tance because in Cxcl13/mice, B1 cells
as well as milky spots are absent from the
pleural and peritoneal cavities (Ansel670 Immunity 30, May 22, 2009 ª2009 Elsevet al., 2002). As a consequence,Cxcl13/
mice, as well as mice deficient for the
CXCL13 receptor, CXCR5, have strongly
reduced titers of natural antibodies (Ansel
etal., 2002;Hopkenetal., 2004).Therefore,
milky spots are an important source of
natural antibodies.
Because milky spots mainly consist
of macrophages and B1 cells, and are
described to lack dendritic cells as well as
follicular dendritic cells, controversy exists
as to whether tomark these milky spots as
secondary lymphoidorgans. In this issueof
Immunity, Rangel-Moreno et al. (2009)
addressed the immunological potential of
milky spots in the absence of lymph nodes,
spleen, and Peyer’s patches. Here, they
used splenectomized lymphotoxin-alpha
(LTa)-deficient mice (Lta/), which as
a result of their deficiency already lacked
lymph nodes and Peyer’s patches. These
animals, devoid of secondary lymphoid
organs, were reconstituted with wild-type
bone marrow (SLP mice) and compared
to irradiated C57BL/6 mice that were simi-
larly reconstituted with wild-type boneier Inc.marrow. Antigens injected into the perito-
neal cavity of SLP mice were shown to
collect in the milky spots, resulting in the
generation of antigen-specific antibodies.
Furthermore, germinal center B cell res-
ponses, supporting isotype switching,
somatic hypermutation, and some affinity
maturation, aswell asproliferationofTcells
in response to intraperitoneally injected
antigens, could be observed in the milky
spots.Not only are thesemilky spots occu-
pied by locally activated lymphocytes, but
also lymphocytes that encounter antigens
elsewhere were shown to recirculate
through the milky spots. These experi-
ments clearly identified the milky spots
as part of the general surveillance route
of antigen-experienced lymphocytes in
search for their antigen.
What does it take to enter and leave the
milky spots? Milky spots contain high
endothelial venules (HEVs) that express
the peripheral lymph node addressin
(PNAd) as well as the mucosal addressin
(MAdCAM-1), permitting entry of lympho-
cytes from the bloodstream into the milky
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eno et al., 2009). In fact, milky spots were
proposed to be the port of entry for B1
cells that migrate from the bloodstream
toward the peritoneal cavity (Ansel et al.,
2002). For the entry of B2 cells into the
milky spots, only a4b7-MAdCAM-1 inter-
action was shown to be essential,
whereas L-selectin was not needed (Ber-
berich et al., 2008). However, the entry
from the bloodstream into the milky spots
must have additional requirements, given
that the cellular composition of the milky
spots is very different from lymph nodes
and Peyer’s patches, which express the
same addressins on HEVs. In addition,
Rangel-Moreno et al. (2009) showed that
a flow from the peritoneal cavity to the
milky spots allows entry of antigens as
well as lymphocytes into the milky spots.
For lymphocytes, this process requires
receptors that are sensitive to pertussis
toxin treatment. Altogether, it seems that
cells enter the milky spots from the blood-
stream, whereas they may thereafter
move freely from the milky spots to the
Figure 1. Schematic Overview of Milky Spot
Function, Architecture, and Formation
Milky spots are formed by clustered B cells, with
high endothelial venules, CD11c+ cells, and some
T cells within the B cell areas. CXCL13-producing
cells, which colocalize with CD11b+ and FDCM1+
cells, are positioned in a cup-like structure around
the B cell clusters. In thesemilky spots, B and T cell
activation can take place, and germinal centers,
supporting isotype switching, somatic hypermuta-
tion, and some affinity maturation, can also be
found.peritoneal cavity and back to the milky
spots.
The overall architecture of the milky
spots is unique because theBcell clusters
do not appear to contain centrally posi-
tioned networks of follicular dendritic cells
(FDCs). FDCs in conventional lymphoid
organs are located in the center of B cell
follicles and express CD35 and CD21, as
well as FDCM1 and FDCM2, while they
produce CXCL13. In milky spots, how-
ever, only some expression of CD35 could
be detected in the center of the B cell
clusters, whereas expression of CXCL13
was very uncharacteristically located on
the outside of these clusters. Expression
of CXCL13 colocalized with FDCM1+ and
CD11b+ cells. The lack of conventional
FDCnetworksmayaccount for the reduced
ability to support affinity maturation in mice
that only contain milky spots (Rangel-Mor-
eno et al., 2009).
Not only are milky spots different from
lymph nodes and Peyer’s patches in their
cellular composition and morphology, but
also their formation seems to followdistinct
cues. In man, the formation of milky spots
starts at 20 weeks of gestation, when clus-
ters of monocytes and macrophages can
be observed, and true milky spots are
apparent at week 35. This development is
clearlymuch later than thatofhuman lymph
nodes, which can be dissected out starting
at week 13 of gestation (Cupedo et al.,
2009). For the formation of lymph nodes
and Peyer’s patches, it is now well estab-
lished that lymphoid tissue inducer cells
(LTi cells), expressing LTab, trigger
lymphoid tissue stromal organizer cells
that express the lymphotoxin-b receptor
(LTbR). This interaction, which leads to the
production of chemokines, expression of
adhesionmolecules, and synthesis of cyto-
kines, is required for the formation of LNs
andPPs (Vondenhoff et al., 2009). Formilky
spot formation, Rangel-Moreno et al.
(2009) show that LTi cells are dispensable
and thus that milky spots follow a distinct
developmental program. Although milky
spots are strongly reduced in absence of
LTa, LTa is not crucial to induce essential
chemokines because CXCL13 was nor-
mally expressed in the omentum of Lta/
mice. The function of LTa is more likely to
be related to regulating the function of
HEVs, which are absent in milky spots of
Lta/ mice. The importance of LTbR
signaling for HEV function and mainte-
nance has been reported for lymph nodesImmunity(Browning et al., 2005). It is tempting to
speculate that HEVs are in fact essential
for the maintenance of milky spots.
Absolutely required for milky spots
formation is the chemokine CXCL13, and
in analogy with the development of lymph
nodes and Peyer’s patches, the cells that
make CXCL13 could be denoted as ‘‘orga-
nizer cells.’’ Rangel-Moreno et al. (2009)
show that CXCL13 expression colocalizes
inCD11b+cells,presumablymacrophages,
and stromal cells in an atypical cup-like
structure around the B cell areas (Figure 1).
In linewith this is the reported expression of
CXCL13 by peritoneal macrophages as
well as radio-resistant cells in the omentum
(Ansel et al., 2002). Therefore, these
CXCL13-producing stromal cells and
macrophages can be considered as the
milky-spot-organizing cells. The macro-
phages in the omentum certainly fulfill the
requirement of organizer cells because in
parabiosed mice (mice with joined blood
circulation), only 10% of these cells were
shown to be replaced by cells from the
partner over a period of 8 weeks (Ansel
et al., 2002) and are thus sessile cells that
could organize a structure.
The inducing signal for CXCL13 expres-
sion is, unlike in LN and PP development,
not delivered by LTi cells, B cells, LTa,
LTb, or TNFa (Ansel et al., 2002; Rangel-
Moreno et al., 2009). One can envision that
activation of macrophages and perhaps
even stromal cells, i.e., by bacterial
encounter or particulate antigens, may
lead to the induction of CXCL13 within the
milky spots. Consistent with this model is
the observation that germ-free BALB/c
micehavestrikingly reduced titersof natural
antibodies to phosphorylcholine, a cell-
surface component of several bacteria
(Gearhart et al., 1975). This is similar to
Cxcl13/ mice, which lack milky spots.
Perhaps also CXCL13 expression in the
omentum is strongly reduced in germ-free
mice, consequently leading to reduction or
absence of milky spots. Indeed, germ-free
ratswere reported to have strongly reduced
numbersofmilky spots (Beelen et al., 1980).
The localization of the CD11b+ cells in the
omentum seems to be independent of
CXCL13 because these cells were present
in distinct areas of the omentum in
Cxcl13/ mice and it is therefore likely
that additional signals that determine the
position of CD11b+ cells are involved in
milky spot formation. It remains to be seen
whether their positioning is determined30, May 22, 2009 ª2009 Elsevier Inc. 671
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Previewsduring a certain time window in develop-
ment. Future studies will also have to
resolve whether indeed bacterial compo-
nents and perhaps other stimuli evoke the
expression of CXCL13 in the peritoneal
cavity.
Now that we know that activation of T
lymphocytes can take place in the milky
spots it remains to be seen whether these
cells will subsequently leave the milky
spots and if so, to which part of the body
they preferentially migrate. Analysis of
homing receptors expressed on lympho-
cytes activated in milky spots should give
a first indication. Furthermore, the associa-
tion of the omentum with the gastrointes-
tinal tract makes one wonder whether
lymphocyte subsets that are characteristi-
cally associated with the mucosal immune672 Immunity 30, May 22, 2009 ª2009 Elsesystem, such as Treg cells, Th17 cells,
and IgA-producing B cells, are also found,
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